Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Advances In™ Hematology: New Therapeutic Options to Treat AL Amyloidosis

Release Date: November 30, 2021
Expiration Date: November 30, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the management of immunoglobulin light-chain (AL) amyloidosis, with a forward-looking perspective on how new diagnostic tools, guidelines, and therapies might impact clinical practice. An overview of AL amyloidosis, along with current and emerging diagnostic and treatment strategies, will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward hematologists, cardiologists, nephrologists, neurologists, and other physicians involved in the treatment and management of amyloidosis.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Discuss clinical presentation and logistical considerations key to facilitate diagnosis of AL amyloidosis
Incorporate strategies for the differential diagnosis of AL amyloidosis
Assess the efficacy and safety of evolving approaches for amyloidosis in the context of risk stratification and monitoring for therapeutic response

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Faculty

Vaishali Sanchorawala, MD
Professor of Medicine
Boston University School of Medicine
Director, Amyloidosis Center
Director, Stem Cell Transplant Program
Boston Medical Center
Boston, MA

Disclosures: Grant/Research Support: Celgene, Takeda Pharmaceutical, Prothena, Caelum Biosciences, Karyopharm Therapeutics, Janssen Pharmaceuticals, Oncopeptides, Sorrento Therapeutics. Consultant: Pfizer, AbbVie, Regeneron Pharmaceuticals, Proclara Biosciences, Protego Biopharma, Telix Pharmaceuticals, Janssen Pharmaceuticals, Prothena.

Omar K. Siddiqi, MD
Assistant Professor
Department of Medicine
Boston Medical Center
Boston University School of Medicine
Boston, MA

Disclosures: Consultant: Janssen Pharmaceuticals

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.